TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. raised its position in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 88.2% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 143,051 shares of the company’s stock after buying an additional 67,027 shares during the period. Brown Brothers Harriman & Co. owned about 0.27% of TScan Therapeutics worth $712,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of TCRX. Great Point Partners LLC purchased a new position in shares of TScan Therapeutics in the 2nd quarter valued at about $5,504,000. Bank of Montreal Can acquired a new stake in TScan Therapeutics in the second quarter valued at approximately $749,000. Bank of New York Mellon Corp purchased a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $682,000. Marshall Wace LLP raised its stake in shares of TScan Therapeutics by 60.8% during the 2nd quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after buying an additional 116,316 shares during the period. Finally, Troluce Capital Advisors LLC purchased a new position in shares of TScan Therapeutics during the 2nd quarter valued at approximately $543,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Stock Performance

Shares of TCRX stock opened at $4.64 on Wednesday. TScan Therapeutics, Inc. has a fifty-two week low of $3.92 and a fifty-two week high of $9.69. The stock’s fifty day moving average is $5.12 and its two-hundred day moving average is $6.28. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.56 and a current ratio of 9.56.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.86 million. As a group, research analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Barbara Klencke bought 5,000 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was acquired at an average cost of $5.29 per share, with a total value of $26,450.00. Following the purchase, the director now directly owns 45,000 shares of the company’s stock, valued at $238,050. The trade was a 12.50 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.76% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Tuesday, November 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Tuesday, November 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, TScan Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.